Company scientists, either individually or collectively, hold over 400 patents. NanoPharmaceuticals LLC has a very broad-based portfolio of 57 patent applications, 34 of which have already been allowed.
Orphan Drug Designations
The FDA has granted the Company Orphan Drug Designations for its treatment modalities for glioblastoma, pancreatic cancer, AML and neuroblastoma.
If and when the Company’s compound for neuroblastoma obtains approval for commercial sale, NanoPharmaceuticals anticipates receiving a priority review voucher from the FDA.